Zentalis Pharmaceuticals (ZNTL) PT Lowered to $28 at UBS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts ZNTL Hot Sheet
Price: $2.21 -8.3%
Rating Summary:
10 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
10 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
UBS analyst Eliana Merle lowered the price target on Zentalis Pharmaceuticals (NASDAQ: ZNTL) to $28.00 (from $52.00) while maintaining a Buy rating.
You May Also Be Interested In
- Zentalis reports overall survival data for ovarian cancer drug at ESMO
- Tango Therapeutics Inc. (TNGX) PT Raised to $55 at Stifel
- Zentalis reports survival data for azenosertib in ovarian cancer trial
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
